Global Equities Roundup: Market Talk

Dow Jones
Oct 30

The latest Market Talks covering Equities. Published exclusively on Dow Jones Newswires throughout the day.

1300 ET - ServiceNow's outlook has investors worried, but its underlying business is still promising, according to Oppenheimer in a note. ServiceNow's stock plunged 25% after the company beat expectations by a narrower margin than before and implied a slowdown in 4Q cRPO [current remaining performance obligations], analysts Brian Schwartz and Idan Gutkind say. These elements leave concerns about organic growth durability, they say. ServiceNow's AI momentum hasn't established a clear path to speeding up organic growth, according to the analysts. However, they believe the stock is worth buying because ServiceNow has an expanding opportunity with AI and a differentiated growth profile. (katherine.hamilton@wsj.com)

1257 ET - Novartis might need to use an event with investors next month to explain which of the drugs it has in the pipeline will drive sales growth next decade, Bernstein analysts say in a research note. The Swiss drugmaker expects top-line growth in the 2030s in the mid-single-digit percentage range, but current consensus estimates project sales decline to decline by 5% annually between 2031 and 2037, the analysts say. "We understand that the company's aim is to help investors bridge from the current consensus to management's mid-single digit growth aspiration by identifying 1-3 organic mid-stage pipeline assets in each of the company's key therapeutic areas," the analysts add. Bernstein trims its target price on the stock to 127.08 Swiss francs from 132.84 francs. Shares close 2.4% higher at 132.30 francs. (adria.calatayud@wsj.com)

1248 ET - ServiceNow's latest results didn't convince investors that it's building momentum, JPMorgan analysts say. Investors are primarily concerned about a projected slowdown in the company's cRPO [current remaining performance obligations] metric, the analysts say. The slowdown is largely due to ServiceNow changing the scope of the cRPO metric to remove certain revenue drivers, the analysts say. The analysts think cRPO will eventually recover, as there are signs of strength in the underlying business. ServiceNow tumbles 25%.(katherine.hamilton@wsj.com)

1241 ET - Genmab scored a "hat-trick" in the fourth quarter, delivering positive results for all three late-stage studies it was due to read out, Jefferies analysts say in a research note. The Danish biotech reported positive results for its petosemtamab drug candidate in trial with head and neck cancer patients with metastasis, opening up a sales opportunity that Jefferies estimates at $3.5 billion. The study results could pave the way for an additional $3.5 billion sales opportunity in locally advanced head and neck cancer, which is currently overlooked by the market, the analysts say. It will be key to see detailed data on the proportion of patients that saw their cancers shrank or disappeared to help cross-trial comparisons, they add. Shares fall 2.6%, but are still up 43% since the start of the week. (adria.calatayud@wsj.com)

1232 ET - Google's Search slowdown in the third quarter is a navigable problem, but it could weigh on shares at least through the fourth quarter, JPMorgan analysts write in a note, lowering their price target by $50 to $375. The monetization headwinds in AI Mode could respark concerns of an AI Search air pocket, the analysts write. "Search also faces tough comps & bigger FX headwinds in 4Q, & AI Mode monetization may take some time to kick in," they write. "This could keep pressure on Google shares near-term, or make them range-bound." Shares of Google parent Alphabet drop 12% to $282.57. (elias.schisgall@wsj.com)

1226 ET - The deceleration in Google's 3Q search revenue raises questions about the company's monetization of AI Mode and AI Overview, UBS analysts write in a note, lowering their price target to $332 from $380. "Google struck what was a more measured/deliberate tone around monetization of incremental AI queries, which to us suggests a lower ad revenue growth trendline than we had anticipated," the analysts write, adding that the company took a "measured approach to monetization" even prior to AI. The third-quarter search showing compares unfavorably to Meta Platforms' revenue growth, the analysts add, noting that a Meta AI search product may be intensifying competition risk. Shares in Google parent Alphabet fall 12% to $282.76. (elias.schisgall@wsj.com)

1225 ET - D.R. Horton says its fiscal 2027 guidance has "wider ranges than usual" citing continued uncertainty across the broader economy. "We expect affordability constraints, higher mortgage rates and cautious consumer sentiment to continue to pressure new home demand," SVP of Communications Jessica Hansen says on a call with analysts. For the year, the homebuilder currently expects revenue of $30 billion to $32 billion, missing Wall Street estimates. (connor.hart@wsj.com)

1222 ET - GSK is entering a period of more limited earnings momentum, with plans to increase research-and-development spending leaving the U.K. drugmaker little room to beat expectations and raise guidance, Jefferies analysts say in a research note. The company has assembled a portfolio of assets that can take it to its 40 billion-pound revenue target for 2031, the analysts say. "With earlier pipeline de-risking increasingly recognized and the next major proof-points further away, we no longer see enough near-term upside to justify a buy and move to hold," Jefferies says. Jefferies also lowers its target price to 21 pounds from 25 pounds. Shares fall 1.3% to 18.07 pounds.(adria.calatayud@wsj.com)

1211 ET - Eli Lilly sees further runway ahead after getting a strong start with the Bridge program, a federal initiative that allows eligible Medicare beneficiaries to get insurance coverage for GLP-1 drugs like Lilly's Zepbound and Foundayo, as well as Novo Nordisk's Wegovy. "It's still early days," says Ilya Yuffa, president of Lilly USA, during a call with analysts. "While it's performing above our expectations, we see continued opportunity here to expand access and utilization." (kelly.cloonan@wsj.com)

1208 ET - D.R. Horton's gross profit margin on home-sales revenue was 19.5% in its fiscal fourth quarter, down sequentially from the June quarter and below the company's expectations, SVP of Communications Jessica Hansen says on a call with analysts. "Market conditions became more challenging as the quarter progressed, which limited our ability to offset higher costs with pricing," she says, adding that higher-than-average litigation costs accounted for the remainder of the decrease. Looking ahead, D.R. Horton expects continued pressure on home-sales gross margin in the current quarter, reflecting lower average sales prices and higher incentive costs at current mortgage rates. "We expect our incentive levels to remain elevated in fiscal 2027," Hansen adds. (connor.hart@wsj.com)

1155 ET - Eli Lilly expects its diabetes drug Mounjaro to maintain its leadership in the U.S., finance chief Lucas Montarce says during a call with analysts. In the latest quarter, Mounjaro's U.S. revenue gained 41% to $5 billion. Montarce also pointed to strength for Mounjaro outside of the U.S. in the period, with those sales up 93% to $5.7 billion. Overall, Mounjaro sales gained 65% to $10.72 billion in the quarter. (kelly.cloonan@wsj.com)

1150 ET - Eli Lilly says the Bridge program is boosting sales of its GLP-1 drugs in the U.S., and a key driver behind its raised full-year revenue guidance. The program, which started in July, is a federal initiative that allows certain Medicare beneficiaries to get insurance coverage for FDA-approved GLP-1 weight loss drugs. "We're encouraged to see the strong uptake of the bridge program," Chief Executive David Ricks says during a call with analysts. Ricks says seven out of ten new Bridge patients are starting on a Lilly obesity medication.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10